Sign inJoin waitlistJoin the waitlist

Aarti Bhatia

Clinical Research Team Leader, Head and Neck Cancers Program · Yale-New Haven Hospital

Credentials: · · · · · ·

History

Yale-New Haven Hospital · Yale School of Medicine
Present

Hematology and Medical Oncology
Fox Chase Cancer Center
2012–2015
Fox Chase Cancer Center
2012–2015
Johns Hopkins University School of Medicine
2009–2012
University of Texas School of Public Health
TN Medical School
2003–2007

Research

Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Review · Drugs · 2023 · First of 2 authors · Corresponding · 207 citations
Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Review · Journal of Clinical Oncology · 2015 · First of 2 authors · 105 citations
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy
Head & Neck · 2010 · First of 10 authors · 67 citations

Barbara Burtness
18 papers
Benjamin Judson
7 papers
Saral Mehra
7 papers
Wendell Yarbrough
7 papers
Henry Park
6 papers · 1 as a resident
Zain Husain
4 papers
HD
Hari Deshpande
3 papers
SC
Shayan Cheraghlou
3 papers
Cheryl Zogg
2 papers
Conor Steuer
2 papers
EY
Emrullah Yilmaz
2 papers
Heather Edwards
2 papers · 2 as a resident

Clinical trials

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Principal investigator · Active not recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2023–2027
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Principal investigator · Completed · Phase 2
Yale University
2017–2026
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Site PI · Not yet recruiting · Phase 3
Corbus Pharmaceuticals Inc.
2026–2029
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2030